NBI-31772 (Standard)

NBI-31772 (Standard) is the analytical standard of NBI-31772. This product is intended for research and analytical applications. NBI-31772 is a non-selective IGFBP inhibitor (Ki=47 nM) . NBI-31772 has neuroprotective effects and reduces infarct volume during cerebral ischemia. NBI-31772 can also restore or enhance proteoglycan synthesis in osteoarticular chondrocytes. In addition, NBI-31772 also increases the effect of IGF3 on zebrafish oocyte maturation[1][2][3][4].

Product Specifications

CAS Number

[374620-70-9]

UNSPSC

12352100

Target

IGF-1R; Reference Standards

Related Pathways

Others; Protein Tyrosine Kinase/RTK

Field of Research

Inflammation/Immunology; Neurological Disease

Smiles

O=C(C1=CC(O)=C(O)C=C1)C2=NC(C(O)=O)=CC3=C2C=C(O)C(O)=C3

Molecular Formula

C17H11NO7

Molecular Weight

341.27

References & Citations

[1]Khawaja XZ. Development of a scintillation proximity assay for human insulin-like growth factor-binding protein 4 compatible with inhibitor high-throughput screening. Anal Biochem. 2007;366 (1) :80-86.|[2]Mackay K B, et al. Neuroprotective effects of insulin-like growth factor-binding protein ligand inhibitors in vitro and in vivo[J]. Journal of Cerebral Blood Flow & Metabolism, 2003, 23 (10) : 1160-1167.|[3]De Ceuninck F, et al. Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes[J]. Arthritis Res Ther, 2004, 6: 1-11.|[4]Li J, et al. Insulin-like growth factor binding proteins inhibit oocyte maturation of zebrafish[J]. General and Comparative Endocrinology, 2019, 281: 83-90.